• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    3/5/21 2:29:18 PM ET
    $RMED
    Medical/Dental Instruments
    Health Care
    Get the next $RMED alert in real time by email
    SC 13G/A 1 rmed1.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information statement pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No.1) Ra Medical Systems, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74933X203 (CUSIP Number) Date of Event Which Requires Filing of this Statement: February 28, 2021 *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 74933X203 13G 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Royce & Associates, LP 52-2343049 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION New York NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 302,583 6 SHARED VOTING POWER 7 SOLE DISPOSITIVE POWER 302,583 8 SHARED DISPOSITIVE POWER 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 302,583 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.36% 12 TYPE OF REPORTING PERSON IA CUSIP No. 74933X203 13G Item 1(a) Name of Issuer: Ra Medical Systems, Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 2070 Las Palmas Drive Carlsbad, CA 92011 Item 2(a) Name of Persons Filing: Royce & Associates, LP Item 2(b) Address of Principal Business Office, or, if None, Residence: 745 Fifth Avenue, New York, NY 10151 Item 2(c) Citizenship: New York Corporation Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 74933X203 Item 3 If this statement is filed pursuant to rules 13d-1(b), or 13d- 2(b), check whether the person filing is a: (a) [ ] Broker or Dealer registered under Section 15 of the Act (b) [ ] Bank as defined in Section 3(a)(6) of the Act (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (d) [ ] Investment Company registered under Section 8 of the Investment Company Act (e) [X] Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 (f) [ ] Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund (g) [ ] Parent Holding Company, in accordance with Rule 13d-1 (b)(ii)(G) (h) [ ] Group CUSIP No. 74933X203 13G Item 4 Ownership The securities reported herein are beneficially owned by one or more registered investment companies or other managed accounts that are investment management clients of Royce & Associates, LP ("RALP"), an indirect majority owned subsidiary of Franklin Resources, Inc.("FRI"). When an investment management contract (including a sub advisory agreement) delegates to RALP investment discretion or voting power over the securities held in the investment advisory accounts that are subject to that agreement, FRI treats RALP as having sole investment discretion or voting authority, as the case may be, unless the agreement specifies otherwise. Accordingly, RALP reports on Schedule 13G that it has sole investment discretion and voting authority over the securities covered by any such investment management agreement, unless otherwise noted in this Item 4. As a result, for purposes of Rule 13d 3 under the Act, RALP may be deemed to be the beneficial owner of the securities reported in this Schedule 13G. Beneficial ownership by investment management subsidiaries and other affiliates of FRI is being reported in conformity with the guidelines articulated by the SEC staff in Release No. 34 39538 (January 12, 1998) relating to organizations, such as FRI, where related entities exercise voting and investment powers over the securities being reported independently from each other. The voting and investment powers held by RALP are exercised independently from FRI (RALP's parent holding company) and from all other investment management subsidiaries of FRI (FRI, its affiliates and investment management subsidiaries other than RALP are, collectively, "FRI affiliates"). Furthermore, internal policies and procedures of RALP and FRI affiliates establish informational barriers that prevent the flow between RALP and the FRI affiliates of information that relates to the voting and investment powers over the securities owned by their respective investment management clients. Consequently, RALP and the FRI affiliates report the securities over which they hold investment and voting power separately from each other for purposes of Section 13 of the Act. Charles B. Johnson and Rupert H. Johnson, Jr. (the "Principal Shareholders") each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI. However, because RALP exercises voting and investment powers on behalf of its investment management clients independently of FRI affiliates, beneficial ownership of the securities reported by RALP is not attributed to the Principal Shareholders. RALP disclaims any pecuniary interest in any of the securities reported in this Schedule 13G. In addition, the filing of this Schedule 13G on behalf of RALP should not be construed as an admission that it is, and it disclaims that it is, the beneficial owner, as defined in Rule 13d 3, of any of such securities. Furthermore, RALP believes that it is not a "group" with FRI affiliates, the Principal Shareholders, or their respective affiliates within the meaning of Rule 13d 5 under the Act and that none of them is otherwise required to attribute to any other the beneficial ownership of the securities held by such person or by any persons or entities for whom or for which RALP or the FRI affiliates provide investment management services. (a) Amount Beneficially Owned: 302,583 (b) Percent of Class: 10.36% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote 302,583 (ii) shared power to vote or to direct the vote __________ (iii) sole power to dispose or to direct the disposition of 302,583 (iv) shared power to dispose or to direct the disposition of __________ Item 5 Ownership of Five Percent or Less of a Class. [ ] Item 6 Ownership of More than Five Percent on Behalf of Another Person. NONE Item 7 Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company. NOT APPLICABLE Item 8 Identification and Classification of Members of the Group. NOT APPLICABLE Item 9 Notice of Dissolution of Group. NOT APPLICABLE CUSIP No. 74933X203 13G Item 10 Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement with respect to it is true, complete and correct. Date: March 05, 2021 By: Daniel A. O'Byrne Vice President
    Get the next $RMED alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RMED

    DatePrice TargetRatingAnalyst
    10/21/2021$12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jenkins David A bought $9,786 worth of shares (19,056 units at $0.51), increasing direct ownership by 6% to 329,856 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/24/24 4:15:18 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $7,086 worth of shares (16,940 units at $0.42), increasing direct ownership by 6% to 310,800 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/22/24 4:15:35 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $6,323 worth of shares (16,263 units at $0.39), increasing direct ownership by 6% to 293,860 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/18/24 4:15:33 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Reminder: Ra Medical Systems Announces Name and Ticker Symbol Changes

      Name change to Catheter Precision, Inc. is effective on August 17, 2023, with trading under new ticker symbol VTAK to begin on August 18, 2023FORT MILL, SC / ACCESSWIRE / August 17, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced that its Board of Directors has approved changing the Company's corporate name to "Catheter Precision, Inc." The effective date of the name change is today, August 17, 2023. The Company has reserved the ticker symbol "VTAK" with the NYSE American, and the Company's common stock is expected to begin trading on the NYSE American under its new name and the new trading symbol effective as of the market open on August 18, 2023. The Company's new website will be unv

      8/17/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Announces Allowance of New Closure Device Patent

      First patent out of six applications on file for LockeT productFORT MILL, SC / ACCESSWIRE / August 14, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced that it has received notification of allowance of the first patent to be issued for the company's LockeT product. Entitled "Vessel Closing Device", the patent to be granted is one in a family of six patent applications on file in the US, and in a number of foreign countries, including the European Community, Japan, and China.David Jenkins, interim CEO of Ra Medical Systems, commented, "We are pleased to see the first of what should be several patents to come about with the LockeT closure device. It is a clever design and invention,

      8/14/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Announces Milestone Achievement for Electrophysiology Division

      Catheter Precision's VIVO System Has Been Utilized in over 1,000 ProceduresFORT MILL, SC / ACCESSWIRE / August 7, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced today that VIVO, the lead product for the electrophysiology division, has been used in more than 1000 ventricular ablation procedures. VIVO, which stands for View Into Ventricular Onset, enables physicians to learn more about patient specific anatomy and better help them plan the ablation procedure. As a result, VIVO aids in reducing overall procedure time benefitting physicians, hospitals and patients."I made a conscious decision to support a pre-commercial roll out with my own capital. I've invested well over $25mm at an ave

      8/7/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Ra Medical Systems with a new price target

      HC Wainwright & Co. initiated coverage of Ra Medical Systems with a rating of Buy and set a new price target of $12.00

      10/21/21 6:17:16 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems downgraded by Maxim Group

      Maxim Group downgraded Ra Medical Systems from Buy to Hold

      3/17/21 8:31:51 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    SEC Filings

    See more
    • Ra Medical Systems Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      1/25/24 4:15:50 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      1/11/24 4:15:46 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Inc. filed SEC Form 8-K: Leadership Update

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      1/4/24 4:20:59 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jenkins David A bought $9,786 worth of shares (19,056 units at $0.51), increasing direct ownership by 6% to 329,856 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/24/24 4:15:18 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $7,086 worth of shares (16,940 units at $0.42), increasing direct ownership by 6% to 310,800 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/22/24 4:15:35 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Jenkins David A bought $6,323 worth of shares (16,263 units at $0.39), increasing direct ownership by 6% to 293,860 units (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/18/24 4:15:33 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Leadership Updates

    Live Leadership Updates

    See more
    • Ra Medical Systems Announces First Quarter Results

      FORT MILL, SC / ACCESSWIRE / June 2, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced financial and company highlights for the first quarter ended March 31,2023. Among the quarter highlights are the following:RMED concluded the acquisition with the private, company Catheter Precision, Inc. ("Catheter"), in January 2023. Catheter is in the MedTech space of cardiac electrophysiology.Catheter onboarded five direct salespersons and several field clinical persons to assist in the broad US launch of its VIVO product, a product utilized to non-invasively determine the source, or earliest activation, of a ventricular arrhythmia.Catheter introduced to the market its new LockeT closure devi

      6/2/23 6:35:00 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Announces Resignation of CEO

      Board Committee Seeking ReplacementFORT MILL, SC / ACCESSWIRE / April 18, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) announced today the resignation of its CEO, Will McGuire, for personal reasons. The resignation will be effective April 28, 2023. In conjunction with his resignation as CEO, Mr. McGuire is also resigning from the RMED board of directors. The Company thanks Mr. McGuire for his service and contributions and wishes him the best in future endeavors.The RMED board of directors, as part of its governance commitment, last month established a committee for examining a transition at the CEO level. Mr. David Jenkins, the Company's Executive Chairman of the Board, will serve as Interim

      4/18/23 8:00:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Announces Change in Chief Financial Officer Position Previous Acting CFO Position Replaced with Permanent Appointment

      FORT MILL, SC / ACCESSWIRE / March 30, 2023 / Ra Medical Systems, Inc. (NYSE:RMED) today announced the appointment of Steven Passey as Chief Financial Officer effective April 1, 2023, replacing Brian Conn, who has been serving as Acting Chief Financial Officer."Steven joins the executive team at a pivotal time in Ra Medical's growth", stated Ra Medical's Executive Chairman of the Board David Jenkins. "His background with publicly traded companies, budget and cost control ensures we will maintain the highest standards as a public company. In addition, he is a seasoned executive who has led M&A transactions as well as numerous equity and debt financing transactions for strategic growth. His ex

      3/30/23 7:30:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Financials

    Live finance-specific insights

    See more
    • Ra Medical Systems Announces Date of Special Shareholder Meeting

      FORT MILL, SC / ACCESSWIRE / February 10, 2023 / Ra Medical Systems (NYSE:RMED) today announced the date of March 21, 2023 as the date of its special shareholder meeting. Shareholders of record as of February 3, 2023 are entitled to vote at the meeting.Among other items, shareholders are requested to vote in favor of a previously announced $8 million private financing, and to vote in favor of the conversion of RMED preferred stock into common stock, the majority of which will not be converted until mid-2024, at the earliest. The preferred stock was issued in connection with the acquisition of Catheter Precision, Inc., earlier this year.About Ra Medical SystemsRa Medical, and its wholly owned

      2/10/23 9:20:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems to Report First Quarter 2022 Financial Results on May 16, 2022

      Ra Medical Systems, Inc. (NYSE:RMED) announces that it will report financial results for the three months ended March 31, 2022 after market close on Monday, May 16. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update. Pre-Registration   Participants can pre-register for the conference call here:           Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

      5/9/22 6:50:00 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • Ra Medical Systems Reports 2021 Fourth Quarter and Full Year Financial Results

      Conference call begins at 4:30 p.m. Eastern time today Ra Medical Systems, Inc. (NYSE:RMED), a medical device company focusing on developing its excimer laser system to treat vascular disease, reports financial results for the three months and full year ended December 31, 2021 and provides a business update. Recent Operational Highlights Filed 510(k) application with the FDA for our next-generation DABRA catheter that incorporates a braided overjacket designed to improve robustness and includes data supporting a six-month shelf life Enrolled 13 subjects in the company's atherectomy pivotal clinical study since mid-November 2021, for a total of 98 subjects enrolled, and received approv

      3/23/22 4:05:00 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care

    $RMED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ra Medical Systems Inc.

      SC 13G - Catheter Precision, Inc. (0001716621) (Subject)

      2/14/24 3:57:22 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Ra Medical Systems Inc. (Amendment)

      SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

      1/16/24 8:15:49 AM ET
      $RMED
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Ra Medical Systems Inc.

      SC 13G - Ra Medical Systems, Inc. (0001716621) (Subject)

      3/31/23 4:15:34 PM ET
      $RMED
      Medical/Dental Instruments
      Health Care